[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"therapy-related-myelodysplastic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:therapy-related-myelodysplastic-syndrome":51},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100264904","phase-2-personalized-nk-cell-therapy-in-cbt-100264904",false,"NCT02727803","Personalized NK Cell Therapy in CBT","Inclusion Criteria:\n\n* Patients must have one of the following hematologic malignancies: acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics including complex karyotype, abnormal \\[abn\\]\\[3q\\], -5\u002F5q-, -7\u002F7q-, abn\\[12p\\], abn\\[17p\\], myeloid\u002Flymphoid or mixed-lineage leukemia \\[MLL\\] gene re-arrangement and t \\[6;9\\]47, fms related tyrosine kinase 3 \\[flt3\\] mutation positive and\u002For evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and\u002For arising from myelodysplastic syndromes (MDS), any disease beyond first remission\n* Myelodysplastic syndrome (MDS): Primary or therapy related, including patients that will be considered for transplant; these include any of the following categories: 1) revised International Prognostic Scoring System (IPSS) intermediate and high risk groups, 2) malondialdehyde (MDA) with transfusion dependency, 3) failure to respond or progression of disease on hypomethylating agents, 4) refractory anemia with excess of blasts, 5) transformation to acute leukemia, 6) chronic myelomonocytic leukemia, 7) atypical MDS\u002Fmyeloproliferative syndromes, 8) complex karyotype, abn(3g), -5\u002F5g-, -7\u002F7g-, abn(12p), abn(17p)\n* Acute lymphoblastic leukemia (ALL): Induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease; patients in first remission are eligible if they are considered high risk, defined as any of the following detected at any time: with translocations 9;22 or 4;11, hypodiploidy, complex karyotype, secondary leukemia developing after cytotoxic drug exposure, and\u002For evidence of minimal residual disease or acute biphenotypic leukemia, or double hit non-Hodgkin's lymphoma\n* Non-Hodgkin's lymphoma (NHL) in second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant); relapsed double hit lymphomas; patients with options for treatment that are known to be curative are not eligible\n* Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease following a minimum of two lines of standard therapy\n* Chronic myeloid leukemia (CML) second chronic phase or accelerated phase\n* Hodgkin's disease (HD): Induction failures, after first complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant), or those with active disease\n* Multiple myeloma: stage II or III, symptomatic, secretory multiple myeloma requiring treatment\n* A person (such as a haploidentical family member) or unit of cord blood must be identified as a source of back-up cells source in case of engraftment failure\n* Patient age criteria: age \\>= 15 and =\\\u003C 45 years (myeloablative regimen 1; age \\>= 15 and =\\\u003C 80 years (nonmyeloablative regimen 2) at the discretion of the investigator(s); age \\>= 15 and =\\\u003C 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy may receive reduced intensity regimen 3\n* Performance score of at least 60% by Karnofsky\n* Left ventricular ejection fraction of at least 40% (myeloablative regimen 1, reduced intensity regimen 3)\n* Left ventricular ejection fraction of at least 30% (nonmyeloablative regimen 2)\n* Pulmonary function test (PFT) demonstrating an adjusted diffusion capacity of least 50% predicted value for hemoglobin concentration (myeloablative regimen 1, reduced intensity regimen 3)\n* Serum creatinine within normal range, or if serum creatinine outside normal range, then renal function (measured or estimated creatinine clearance or glomerular filtration rate \\[GFR\\]) \\> 40mL\u002Fmin\u002F1.73 m\\^2\n* Serum glutamate pyruvate transaminase (SGPT)\u002Fbilirubin \\\u003C to 2.0 x normal (myeloablative regimen 1), reduced intensity regimen 3; SGPT\u002Fbilirubin \\\u003C to 4.0 x normal (nonmyeloablative regimen 2)\n* Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months\n* Patients with options for treatment that are known to be curative are not eligible\n* Patients enrolled in this study may be enrolled on other supportive care investigational new drug (IND) studies at the discretion of the principal investigator (PI)\n\nExclusion Criteria:\n\n* Human immunodeficiency virus (HIV) positive; HIV results will be determined by nucleic acid testing\n* Uncontrolled serious medical condition such as persistent septicemia despite adequate antibiotic therapy, decompensated congestive heart failure despite cardiac medications or pulmonary insufficiency requiring intubation (excluding primary disease for which cord blood \\[CB\\] transplantation is proposed), or psychiatric condition that would limit informed consent\n* Active central nervous system (CNS) disease in patient with history of CNS malignancy\n* Availability of appropriate, willing, human leukocyte antigen (HLA)-matched related stem cell donor","ALL","15 Years","80 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1\u002Fx recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2\u002FC2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51],"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Biphenotypic Leukemia","Acute Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Acute Myeloid Leukemia With Variant MLL Translocations","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Chemotherapy-Related Leukemia","Chronic Myelomonocytic Leukemia","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","ISS Stage II Plasma Cell Myeloma","ISS Stage III Plasma Cell Myeloma","Myelodysplastic Syndrome","Myelodysplastic Syndrome With Excess Blasts","Myelodysplastic Syndrome With Gene Mutation","Myelodysplastic\u002FMyeloproliferative Neoplasm","Previously Treated Myelodysplastic Syndrome","Recurrent Acute Myeloid Leukemia","Recurrent Adult Acute Myeloid Leukemia","Recurrent Hodgkin Lymphoma","Recurrent Non-Hodgkin Lymphoma","Refractory Acute Lymphoblastic Leukemia","Refractory Adult Acute Lymphoblastic Leukemia","Secondary Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","RECRUITING","2026-05-20",{"date":55,"type":56},"2026-05-22","ACTUAL",{"date":58,"type":56},"2016-05-19",{"date":60,"type":20},"2027-05-31",{"name":62,"class":63},"M.D. Anderson Cancer Center","OTHER",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":78,"conditions":79,"keywords":90,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100461746","phase-1-venetoclax-basket-trial-for-high-risk-hematologic-malignancies-100461746","NCT05292664","Venetoclax Basket Trial for High Risk Hematologic Malignancies","A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies","Inclusion Criteria\n\nCohort A Inclusion Criteria:\n\n* MDS, AML arising from MDS (MDS\u002FAML), therapy related myeloid neoplasm (tMDS\u002FAML) meeting at least one of the following criteria:\n\n  * MDS with excess blasts (\\>10%)\n  * MDS with blasts \\\u003C10% with high-risk features\n  * MDS refractory to initial treatment\n  * Relapsed MDS\n  * MDS\u002FAML: May be newly diagnosed or relapsed\u002Frefractory disease.\n  * Therapy related myeloid neoplasm (tMDS\u002FAML): May be initial or relapsed\u002Frefractory disease.\n\n    * Note: MDS or MDS\u002FAML may be derived from a germline predisposition to myeloid malignancy as long as that condition does not confer increased toxicity to treatment.\n* Age ≤ 40 years of age, except the following subjects that must be \\\u003C18 years to enroll\n\n  * Subjects with MDS\u002FAML that have not received prior therapy\n  * Subjects enrolled onto Dose level -2.\n* Lansky\u002FKarnofsky performance status ≥ 50%\n* Participants must have fully recovered from the acute toxic effects of all and meet all of the following criteria:\n\n  * Myelosuppressive chemotherapy: 14 days, or 5 half-lifes (whichever is shorter) must have elapsed since the completion of myelosuppressive therapy. Individuals may have received any of the following medications without a \"wash-out\" period\n\n    * Standard maintenance therapy: dexamethasone\u002Fprednisone, vincristine, 6MP, low dose methotrexate)\n    * Hydroxyurea\n    * Intrathecal chemotherapy with methotrexate, hydrocortisone and\u002For cytarabine.\n  * Radiation therapy (XRT):\n\n    * Total Body Irradiation (TBI) or cranial radiation therapy: Must have been completed more than 90 days prior to study entry\n    * XRT for chloroma does not require a washout period.\n    * Palliative XRT does not require a washout\n  * Small molecule inhibitors (BCR-ABL or FLT3 inhibitors, for example): 7 days, or 5 half-lifes, whichever is shorter) must have elapsed since the completion of therapy. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.\n  * Immunotherapy: At least 30 days after the administration of any type of immunotherapy, including, but not limited to, tumor vaccines, chimeric antigen receptor (CAR) therapy, other immune effector cell therapy and checkpoint inhibitors.\n  * Monoclonal antibodies: At least 3 half-lives of the antibody\n  * Prior hematopoietic stem cell transplant (HSCT):\n\n    * Allogeneic HSCT \\> 90 days of study entry\n    * No evidence of graft-versus-host-disease (GVHD)\n  * Adequate organ function, as defined by\n\n    * Serum alanine aminotransferase (ALT) ≤5X upper limit of normal (ULN)\n    * Direct bilirubin ≤ 3X\n    * Ejection fraction ≥ 50% or shortening fraction of ≥ 24% on screening echocardiogram.\n  * Female participants of childbearing potential must have a negative urine or serum HCG prior to study entry and at the start of therapy. All females of childbearing potential must refrain from breastfeeding during study participation, and all male and females of childbearing potential must agree to use an effective form of contraception (abstinence, hormonal, or barrier) prior to study entry, for duration of participation, and for a minimum of 30 days following the last dose of treatment.\n\nCohort B Inclusion Criteria\n\n* MDS, MDS\u002FAML, therapy related myeloid neoplasm (tMDS\u002FAML) that is derived from the following germline disorders:\n\n  * Dyskeratosis Congenita or associated telomeropathies\n  * Fanconi Anemia\n  * Nijmegen Breakage\n  * Other related disorders with high risk of toxicity may be eligible for this cohort after discussion with the Sponsor-Investigator.\n* And meets at least one the following disease characteristics:\n\n  * MDS with excess blasts (\\>10%)\n  * MDS with blasts \\\u003C10% with high-risk features\n  * MDS refractory to initial treatment\n  * Relapsed MDS\n  * MDS\u002FAML: May be newly diagnosed or relapsed\u002Frefractory disease.\n  * Therapy related myeloid neoplasm (tMDS\u002FAML): May be initial or relapsed\u002Frefractory disease.\n* Age ≤ 40 years of age\n* Lansky\u002FKarnofsky performance status ≥ 50%\n* Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and meet all of the following criteria:\n\n  * Myelosuppressive chemotherapy: 14 days, or 5 half-lifes (which ever is shorter) must have elapsed since the completion of myelosuppressive therapy. Individuals may have received any of the following medications without a \"wash-out\" period\n\n    * Standard maintenance therapy: dexamethasone\u002Fprednisone, vincristine, 6MP, low dose methotrexate\n    * Hydroxyurea\n    * Intrathecal chemotherapy with methotrexate, hydrocortisone and\u002For cytarabine.\n  * Radiation therapy (XRT):\n\n    * Total Body Irradiation (TBI) or cranial radiation therapy: Must have been completed more than 90 days prior to study entry\n    * XRT for chloroma does not require a washout period.\n    * Palliative XRT does not require a washout\n  * Small molecule inhibitors (BCR-ABL or FLT3 inhibitors, for example): 7 days, or 5 half-lifes, whichever is shorter) must have elapsed since the completion of therapy. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.\n  * Immunotherapy: At least 30 days after the administration of any type of immunotherapy, including, but not limited to, tumor vaccines, chimeric antigen receptor (CAR) therapy, other immune effector cell therapy and checkpoint inhibitors.\n  * Monoclonal antibodies: At least 3 half-lives of the antibody\n  * Prior hematopoietic stem cell transplant (HSCT): Must meet all of the following conditions:\n\n    * Allogeneic HSCT \\> 90 days of study entry\n    * No evidence of graft-versus-host-disease (GVHD)\n* Adequate organ function, as defined by\n\n  * Serum alanine aminotransferase (ALT) ≤5X upper limit of normal (ULN)\n  * Direct bilirubin ≤ 3X upper limit of normal for age and institution.\n* Ejection fraction ≥ 50% or shortening fraction of ≥ 24% on screening echocardiogram.\n* Because of the teratogenic effects of venetoclax on developing fetuses, female participants of childbearing potential must have a negative urine or serum HCG prior to study entry and at the start of therapy. All females of childbearing potential must refrain from breastfeeding during study participation, and all male and females of childbearing potential must agree to use an effective form of contraception (abstinence, hormonal, or barrier) prior to study entry, for duration of participation, and for a minimum of 30 days following the last dose of treatment.\n\nCohort C Inclusion Criteria\n\n* Part I: B-cell or T-cell acute lymphoblastic leukemia (ALL), mixed phenotype acute lymphoblastic leukemia (MPAL) or lymphoblastic lymphoma (LBL) in first or greater relapse or refractory to at least 1 prior remission induction attempt.\n\n  * For ALL\u002FMPAL: Bone marrow involvement ≥ 5% by aspirate morphology or ≥ 1% assessable by flow cytometry or validated molecular minimal residual disease (MRD) testing\n  * For LBL: Radiographically detectable mass or lymph node involvement\n* Part II: Histologically confirmed diagnosis of one of the following:\n\n  * T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) in first or greater relapse or refractory to at least 1 prior remission induction attempt.\n\n    * For T-ALL: Bone marrow involvement ≥ 5% by aspirate morphology or ≥ 1% assessable by morphology, flow cytometry or validated MRD testing\n    * For T-LBL (biopsy proven at current or prior relapse): Radiographically detectable mass or lymph node involvement OR\n  * Relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) with bone marrow involvement ≥1% (assessable by morphology, flow cytometry or validated MRD testing) and at least one of the following characteristics:\n\n    * First relapse with adverse biologic determinants as described below:\n\n      * KMT2A rearrangement\n      * Low hypodiploidy, defined as ≤ 40 chromosomes\n      * t(17;19)\n      * IKZF1 deletion (without targetable ABL1 fusion)\n      * Ph-like ALL (without targetable ABL1 fusion)\n      * Other biologic determinants with adverse prognosis in discussion with the Sponsor-Investigator\n    * Early first bone marrow relapse occurring \\\u003C36 months from initial diagnosis\n    * Primary refractory ALL that has failed 1 prior induction attempt\n* Age: ≥ 1 and ≤ 21 years of age\n* Lansky\u002FKarnofsky performance status ≥ 50%\n* Participants must have fully recovered from the acute toxic effects of all prior and meet all of the following criteria:\n\n  * Myelosuppressive chemotherapy: 14 days, or 5 half-lives, whichever is shorter, must have elapsed since the completion of myelosuppressive therapy. Individuals may have received any of the following medications without a \"wash-out\" period:\n\n    * Standard maintenance therapy: dexamethasone\u002Fprednisone, vincristine, 6MP, low dose methotrexate\n    * Hydroxyurea\n    * Intrathecal chemotherapy with methotrexate, hydrocortisone and\u002For cytarabine.\n  * Radiation therapy (XRT):\n\n    * Total Body Irradiation (TBI) or cranial radiation therapy: Must have been completed more than 90 days prior to study entry\n    * XRT for chloroma does not require a washout period.\n    * Palliative XRT does not require a washout\n  * Small molecule inhibitors (BCR-ABL or FLT3 inhibitors, for example): 7 days, or 5 half-lifes, whichever is shorter) must have elapsed since the completion of therapy. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.\n  * Immunotherapy: At least 30 days after the administration of any type of immunotherapy, including, but not limited to, tumor vaccines, chimeric antigen receptor (CAR) therapy, other immune effector cell therapy and checkpoint inhibitors.\n  * Monoclonal antibodies: At least 3 half-lives of the antibody after the last dose of a monoclonal antibody\n  * Prior hematopoietic stem cell transplant (HSCT): Patients who have received HSCT are eligible, but must meet all of the following conditions:\n\n    * Allogeneic HSCT \\> 90 days of study entry\n    * No evidence of graft-versus-host-disease (GVHD)\n* Adequate organ function, as defined by the following laboratory values:\n\n  * Serum alanine aminotransferase (ALT) ≤5X upper limit of normal (ULN), unless deemed secondary to leukemic involvement in discussion with site PI.)\n  * Direct bilirubin ≤ 3X upper limit of normal for age and institution.\n  * Serum amylase ≤ 3X institutional ULN .\n* Cardiac function as defined as below:\n\n  * Ejection fraction ≥ 50% or shortening fraction of ≥ 24% on screening echocardiogram.\n  * Maximum prior cumulative doxorubicin dose ≤ 360 mg\u002Fm2 or equivalent\n* Because of the teratogenic effects of venetoclax on developing fetuses, female participants of childbearing potential must have a negative urine or serum HCG prior to study entry and at the start of therapy. All females of childbearing potential must refrain from breastfeeding during study participation, and all male and females of childbearing potential must agree to use an effective non-hormonal form of contraception (abstinence, barrier) prior to study entry, for duration of participation, and for a minimum of 3 months following the last dose of treatment (as calaspargase pegol can render hormonal contraceptives ineffective).\n\nExclusion Criteria\n\nCohort A Exclusion Criteria\n\n* Use of strong or moderate CYP3A inhibitors\u002Finducers within 3 days of study entry\n* Individuals who have had a stem cell transplant and are still receiving treatment for GVHD or GVHD prophylaxis, or who have evidence of acute GVHD\n* Individuals with known active hepatitis; baseline testing not required.\n* Patients with systemic infection that is exhibiting ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate antibiotics or other treatment.\n* Patients known to have human immunodeficiency virus (HIV) infection; baseline testing for HIV is not required.\n* Pregnant or nursing women are excluded.\n* Individuals with significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.\n\nCohort B Exclusion Criteria\n\n* Use of strong or moderate CYP3A inhibitors\u002Finducers within 3 days of study entry\n* Individuals who have had a stem cell transplant and are still receiving treatment for GVHD or GVHD prophylaxis, or who have evidence of acute GVHD\n* Individuals with known active hepatitis; baseline testing not required.\n* Patients with systemic infection that is exhibiting ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate antibiotics or other treatment.\n* Patients known to have human immunodeficiency virus (HIV) infection; baseline testing for HIV is not required.\n* Pregnant or nursing women are excluded.\n* Individuals with significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.\n\nCohort C Exclusion Criteria\n\n* Use of strong or moderate CYP3A inhibitors\u002Finducers within 3 days of study entry\n* Individuals who have had a stem cell transplant and are still receiving treatment for GVHD or GVHD prophylaxis, or who have evidence of acute GVHD, or who are less than 90 days from stem cell infusion\n* Individuals with known active hepatitis; baseline testing not required.\n* Patients with systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate antibiotics or other treatment.\n* Patients known to have human immunodeficiency virus (HIV) infection; baseline testing for HIV is not required.\n* Pregnant or nursing women are excluded\n* Individuals with significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.\n* Individuals with a history of allergic reactions to any of the agents being used in this trial, with the exception of pegaspargase or calaspargase pegol. Participants with a history of allergy to pegylated formulation of asparasginase are allowed on study but should receive commercial supply of asparaginase Erwinia chrysanthemi (Erwinaze), crisantaspase (Erwinase), or asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) instead of calaspargase pegol (see Sections 6.2.6 and 6.2.7). Individuals with a history of allergy to Erwinaze, Erwinase or Rylaze are excluded from the study.\n* History of asparaginase-associated pancreatitis.\n* Known, active and propagating deep venous thrombus (DVT).\n* Individuals with isolated CNS or testicular relapse.\n* Presence of surface immunoglobulin by flow cytometry and\u002For known t(8;14), t(2;8), or t(8;22).\n* Individuals with a history of a different malignancy are ineligible except for the following circumstances:\n\n  * Individuals are eligible if they have been disease-free for at least 1 year and are deemed by the investigator to be at low risk for recurrence of that malignancy.\n  * Individuals with the following cancers are eligible if diagnosed and treated within the past year: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.","1 Year","40 Years",{"count":75,"type":20},30,[77],"PHASE1","This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS\u002FAML), and acute lymphoblastic leukemia (ALL)\u002Flymphoblastic lymphoma (LBL).\n\nThe names of the study drugs involved in this study are below. Please note this is a list for the study as a whole, participants will receive drugs according to disease cohort.\n\n* Venetoclax\n* Azacitidine\n* Cytarabine\n* Methotrexate\n* Hydrocortisone\n* Leucovorin\n* Dexamethasone\n* Vincristine\n* Doxorubicin\n* Dexrazoxane\n* Calaspargase pegol\n* Hydrocortisone",[80,81,82,83,51,84,85,86,87,88,89],"Myelodysplastic Syndromes, de Novo","Myelodysplastic Syndromes, Secondary","Myelodysplastic Syndromes, Previously Treated","Treatment-Related Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Lymphoblastic Lymphoma, in Relapse","Lymphoblastic Lymphoma, Refractory","Acute Leukemia of Ambiguous Lineage in Relapse","Acute Leukemia of Ambiguous Lineage",[91,92,93,94,95,96,97,98],"Myelodysplastic Syndrome (MDS)","Treatment-related Acute Myelogenous Leukemia","AML arising from MDS","Relapsed or Refractory Acute Lymphoblastic Leukemia","Relapsed or Refractory Acute Lymphoblastic Lymphoma","Relapsed or Refractory MDS","Treatment-related MDS","Relapsed or Refractory Acute leukemia of ambiguous lineage","2026-03-10",{"date":101,"type":56},"2026-03-12",{"date":103,"type":56},"2023-03-29",{"date":105,"type":20},"2030-07-02",{"name":107,"class":63},"Andrew E. Place, MD",5]